Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Medical System Holdings ( (HK:0867) ) just unveiled an announcement.
China Medical System Holdings has announced that its subsidiary, Dermavon Holdings, has had its new drug application for MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody injection, accepted by China’s National Medical Products Administration. This drug, intended for treating moderate-to-severe atopic dermatitis, has shown promising results in clinical trials and is expected to enhance patient adherence due to its four-week dosing schedule. If approved, MG-K10 will enrich the company’s dermatological product portfolio and strengthen Dermavon’s market competitiveness.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings Limited, through its subsidiary Dermavon Holdings Limited, operates in the pharmaceutical industry with a focus on skin health. The company specializes in innovative dermatological treatments and is seeking to expand its market presence by listing on the Main Board of The Stock Exchange of Hong Kong Limited.
Average Trading Volume: 8,434,204
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.3B
See more insights into 0867 stock on TipRanks’ Stock Analysis page.